Dare Bioscience (DARE) Projected to Announce Quarterly Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is expected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.2967) per share and revenue of $0.0020 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.13. The company had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, analysts expect Dare Bioscience to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Dare Bioscience Price Performance

NASDAQ DARE opened at $1.36 on Tuesday. Dare Bioscience has a 1 year low of $1.13 and a 1 year high of $3.78. The stock has a market capitalization of $20.51 million, a PE ratio of -1.43 and a beta of 1.08. The business’s 50-day moving average is $1.81 and its 200 day moving average is $1.89.

Hedge Funds Weigh In On Dare Bioscience

A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Dare Bioscience during the 3rd quarter worth about $37,000. Raymond James Financial Inc. increased its position in shares of Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, LPL Financial LLC purchased a new position in shares of Dare Bioscience in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on DARE. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Friday, July 17th. Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a research note on Saturday, May 23rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.